07 June 2022: Original Paper
Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of Differences Between Alcohol-Related and Non-Alcohol-Related Cirrhosis Candidates
Jan-Paul Gundlach 1EF** , Felix Braun 1AD* , Finn Mötter 1B , Alexander Bernsmeier 1CDE , Pablo Barrio 2E , Nicola Ehmke 1B , Rainer Günther 3B , Holger Hinrichsen 4A , Thomas Becker 1AD , Wolfgang Weinmann 5B , Alexandra Schröck 6C , Michel Yegles 7C , Friedrich Martin Wurst 8ACDEDOI: 10.12659/AOT.936293
Ann Transplant 2022; 27:e936293
Figure 2 Overview of positive biomarker test results in patients with alcohol-related cirrhosis (n=25) or other liver diseases (n=41) in percent. uEtG and hEtG were tested in 65 patients, respectively. For PEth (n=66), patients with liver diseases other than alcohol-related cirrhosis showed a positive test result in over 50% of the cases, which is comparable to patients with alcohol-related cirrhosis. Figure prepared with PowerPoint 2019, Microsoft Corporation, Redmond/Washington, USA.